Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 8.56% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -69.06
2
Flat results in Dec 23
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 6,382 Million ()
NA (Loss Making)
NA
0.00%
-0.12
-17.58%
0.94
Revenue and Profits:
Net Sales:
714 Million
(Quarterly Results - Jun 2025)
Net Profit:
-222 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-28.87%
0%
-28.87%
6 Months
-16.23%
0%
-16.23%
1 Year
76.73%
0%
76.73%
2 Years
16.22%
0%
16.22%
3 Years
-31.03%
0%
-31.03%
4 Years
-47.43%
0%
-47.43%
5 Years
-44.32%
0%
-44.32%
Shanghai Junshi Biosciences Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.97%
EBIT Growth (5y)
8.56%
EBIT to Interest (avg)
-69.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.18
Tax Ratio
0.57%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.97
EV to EBIT
-5.13
EV to EBITDA
-6.99
EV to Capital Employed
0.97
EV to Sales
2.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-18.97%
ROE (Latest)
-18.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
713.50
528.80
34.93%
Operating Profit (PBDIT) excl Other Income
-170.10
-209.20
18.69%
Interest
19.00
18.00
5.56%
Exceptional Items
60.20
-0.30
20,166.67%
Consolidate Net Profit
-222.40
-277.50
19.86%
Operating Profit Margin (Excl OI)
-359.60%
-557.50%
19.79%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 34.93% vs -27.23% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 19.86% vs 34.44% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,088.20
1,638.50
27.45%
Operating Profit (PBDIT) excl Other Income
-1,094.00
-2,410.60
54.62%
Interest
56.10
32.80
71.04%
Exceptional Items
-51.70
-164.80
68.63%
Consolidate Net Profit
-1,496.30
-2,801.90
46.60%
Operating Profit Margin (Excl OI)
-693.70%
-1,695.40%
100.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 27.45% vs -2.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 46.60% vs 6.76% in Dec 2023
About Shanghai Junshi Biosciences Co., Ltd. 
Shanghai Junshi Biosciences Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






